About Inocras
Inocras is a company based in San Diego (United States) founded in 2020 by Jeong Seok Lee and Young Seok Ju. Inocras has raised $83.4 million across 7 funding rounds from investors including Samsung Venture Investment, Big Move Ventures and Dunamu & Partners. Inocras offers products and services including CancerVision, RareVision, and MRDVision. Inocras operates in a competitive market with competitors including Panakeia, Boston Medical Sciences, Nevia Bio, Astrin and Onkolyze, among others.
- Headquarter San Diego, United States
- Founders Jeong Seok Lee, Young Seok Ju
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Inocras Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$83.4 M (USD)
in 7 rounds
-
Latest Funding Round
$31 M (USD), Series B
Aug 03, 2026
-
Investors
Samsung Venture Investment
& 9 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Inocras
Inocras offers a comprehensive portfolio of products and services, including CancerVision, RareVision, and MRDVision.
Whole genome test for profiling solid tumor cancers and detecting mutations.
Whole genome test for diagnosing rare diseases through comprehensive analysis.
Tumor-informed ctDNA test for minimal residual disease detection in research.
Funding Insights of Inocras
Inocras has successfully raised a total of $83.4M across 7 strategic funding rounds. The most recent funding activity was a Series B round of $31 million completed in August 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Inocras
Inocras has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include Samsung Venture Investment, Big Move Ventures and Dunamu & Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Venture capital investments are made in promising startups.
|
Locked | Locked | Locked | |
|
Venture capital firm backed by Dunamu
|
Locked | Locked | Locked |
Investor details for Inocras
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Inocras
Investment portfolio details for Inocras
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Inocras
Detailed financials for Inocras
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Inocras Comparisons
Peer comparison for Inocras
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Inocras
Inocras operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Panakeia, Boston Medical Sciences, Nevia Bio, Astrin and Onkolyze, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
AI-based software is provided for cancer diagnosis and precision treatment.
|
|
| Locked | Locked | Locked |
AI-powered colorectal cancer screening system
|
|
| Locked | Locked | Locked |
Machine learning-enabled platform for early detection of women-related diseases
|
|
| Locked | Locked | Locked |
Early cancer detection is enabled by AI-powered 3D holographic imaging.
|
|
| Locked | Locked | Locked |
Ultrasound images are analyzed by AI platform for cancer detection.
|
|
| Locked | Locked | Locked |
Developer of robotic medical equipment for skin cancer detection
|
Detailed competitors of Inocras
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Inocras
Complete news archive for Inocras
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Inocras
Inocras was founded in 2020.
Inocras is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Jehee Suh is the current CEO of Inocras.
Inocras is a funded company, having raised a total of $83.4M across 7 funding rounds to date.
AI-driven platform provides whole genome insights for cancer and rare diseases. It has developed an IP-protected technology and proprietary whole genome insight platform to improve patient diagnosis and treatment by unlocking the full potential of genomic data.
Inocras's top competitors include Panakeia, Boston Medical Sciences and Spotitearly.
Inocras offers CancerVision, RareVision, and MRDVision.
Inocras has 10 investors. Key investors include Samsung Venture Investment, Big Move Ventures, Dunamu & Partners, Mss, and IMM Investment.